BofA downgraded Galera Therapeutics to Underperform from Buy with a price target of 50c, down from $7, due to failure of lead program avasopasem managnese in RT-induced severe oral mucositis. The firm is simultaneously terminating coverage of the stock.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on GRTX:
